There are currently 45 active clinical trials seeking participants for Rheumatoid Arthritis research studies. The states with the highest number of trials for Rheumatoid Arthritis participants are Florida, California, Texas and Pennsylvania.
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
NCT06859294
Recruiting
The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/23/2025
Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona +19 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT05814627
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 253431, Flagstaff, Arizona +217 locations
Conditions: Rheumatoid Arthritis
Register for Updates
A Study of Baricitinib in Participants With Rheumatoid Arthritis
NCT04086745
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Arizona Research Clinic PLLC, Chandler, Arizona +138 locations
Conditions: Rheumatoid Arthritis
Register for Updates
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
NCT05848258
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Newport Huntington Medical Group, Huntington Beach, California +57 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT03816345
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +51 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Register for Updates
MAD Study of IA-14069
NCT05533372
Recruiting
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of IA-14069 in healthy subjects and in patients with RA on stable dosese of MTX, with preliminary assessment of efficacy in RA patients.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/15/2025
Locations: ICON plc., Lenexa, Kansas
Conditions: Healthy, Rheumatoid Arthritis
Register for Updates
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
NCT06293365
Recruiting
The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). A second cohort will be included... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/12/2025
Locations: Pinnacle Research Group Llc, Anniston, Alabama +35 locations
Conditions: Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Register for Updates
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
NCT04751396
Recruiting
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis, Enteropathic Arthritis, Enteropathic Spondylitis
Register for Updates
Study of GS-0272 in Participants With Rheumatoid Arthritis
NCT06031415
Recruiting
The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA). The primary objectives of this study are to assess the safety and tolerability of multiple ascending doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple doses of GS-0272, in participants with RA.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/01/2025
Locations: Arizona Arthritis & Rheumatology Associates P.C., Glendale, California +15 locations
Conditions: Rheumatoid Arthritis
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462
Recruiting
This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA). The primary objective is to evaluate the effects of IMVT-1402 compared to placebo, as measured by the American College of Rheumatology 20% (ACR20) response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Site Number - 1003, Anniston, Alabama +36 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Early Rheumatoid Arthritis Lung Disease Study
NCT03192267
Recruiting
Extra-articular (outside of joints) disease occurs in approximately 50% of rheumatoid arthritis (RA) patients, with the lung being a common site of involvement. The goals of this study are to investigate and characterize lung disease and its prevalence in early RA participants. This will be done through pulmonary function and high resolution chest computed tomography (CT), questionnaires, and serum studies. Another goal is to find novel biomarkers, such anti-malondialdehyde-acetaldehyde (MAA) an... Read More
Gender:
ALL
Ages:
Between 19 years and 90 years
Trial Updated:
04/28/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Rheumatoid Arthritis
Register for Updates
CD40L Antagonism in Rheumatoid Arthritis (RA)
NCT05306353
Recruiting
The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to TNFi treatment will result in improved clinical disease control in patients with RA who have had an inadequate response to a TNFi.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/23/2025
Locations: University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center, San Francisco, California +4 locations
Conditions: Rheumatoid Arthritis
Register for Updates